Melanoma staging: Varying precision and terminal digit clustering in Breslow thickness data is evident in a population-based study

Veierød, Marit Bragelien; Page, Christian M.; Aaserud, Stein; Bassarova, Assia; Jacobsen, Kari Dolven; Helsing, Per; Robsahm, Trude Eid

doi:10.1016/j.jaad.2018.03.023

Cited by 10 publications

(10 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PASI-75 was achieved in 86% and 85% of patients receiving brodalumab (210 mg dose) in the two separate studies. According to pooled long-term data from AMAGINE-2 and −3, >60% of patients receiving any dose of brodalumab for >2 years (108 weeks) achieved PASI 100 17. A further pooled analysis of AMAGINE-2 and −3 data showed that, in patients who received brodalumab 210 mg every 2 weeks for 52 weeks, PASI 100 was achieved in 63.4% and 62.9% of patients at 52 and 108 weeks, respectively 18.…”

Section: Discussionmentioning

confidence: 99%

“…According to pooled long-term data from AMAGINE-2 and −3, >60% of patients receiving any dose of brodalumab for >2 years (108 weeks) achieved PASI 100 17. A further pooled analysis of AMAGINE-2 and −3 data showed that, in patients who received brodalumab 210 mg every 2 weeks for 52 weeks, PASI 100 was achieved in 63.4% and 62.9% of patients at 52 and 108 weeks, respectively 18. In patients who received ustekinumab for 52 weeks, PASI 100 was achieved in 42.3% of patients, but after switching to brodalumab 210 mg every 2 weeks at week 52, PASI 100 increased to 62.5% at week 108 18…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

<p>Brodalumab for the treatment of moderate-to-severe psoriasis: case series and literature review</p>

Pinter¹,

Bonnekoh²,

Hadshiew³

et al. 2019

CCID

View full text Add to dashboard Cite

Brodalumab, a recombinant fully human monoclonal immunoglobulin IgG2 antibody with high affinity to human interleukin (IL)-17RA, is approved for the treatment of moderate-to-severe plaque psoriasis. In controlled clinical trials, brodalumab 210 mg administered by subcutaneous injection at weeks 0, 1, and 2, then 210 mg every 2 weeks, produced a rapid onset and sustained clinical response. Consistently, >80% of patients achieved PASI-75 and efficacy was maintained for >2 years. The benefits are apparent soon after the start of therapy and are maintained in the long term. Such results, from the reviewed literature, support the findings from 4 'real world' cases in mainstream clinical practice which are reported here. Psoriatic plaques, including on the scalp, nails, soles and palms, were largely resolved, and quality of life improved markedly. Therapeutic success was achieved in patients naïve to biologics (2 cases) and in those responding inadequately to other biologics (2 cases). The high affinity of brodalumab to human IL-17RA blocks the biological activities of the pro-inflammatory cytokines IL-17A, IL-17C, IL-17E, IL-17F, and IL-17A/F heterodimer, resulting in inhibition of the inflammation and clinical symptoms associated with psoriasis. This mechanism of blocking multiple IL-17 family cytokines differs from that of other available biologics which selectively target some parts of the Th-17 axis and may account for the effectiveness of brodalumab in patients poorly responsive to other biologics, a feature which has also been shown where subgroup analysis has been undertaken in clinical trials. The drug is well tolerated during the normal 12-week induction phase and with prolonged treatment (52 to 120 weeks), as it was in the current case series.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

<p>Brodalumab for the treatment of moderate-to-severe psoriasis: case series and literature review</p>

Pinter¹,

Bonnekoh²,

Hadshiew³

et al. 2019

CCID

View full text Add to dashboard Cite

show abstract

“…Preferential overrepresentation of certain terminal digits (terminal digit preference) is a well-known source of measurement error in medicine, including the measurement of malignant tumors [1][2][3]. Some evidence suggests that pathologists measuring breast tumor diameter favor terminal digits of zero or five, though few studies have evaluated this type of measurement error as a primary objective [3][4][5][6].…”

Section: Introductionmentioning

confidence: 99%

Terminal digit preference: a source of measurement error in breast cancer diameter reporting

et al. 2019

Self Cite

View full text Add to dashboard Cite

Objectives: Women diagnosed with breast cancer are offered treatment and therapy based on tumor characteristics, including tumor diameter. There is scarce knowledge whether tumor diameter is accurately reported, or whether it is unconsciously rounded to the nearest half-centimeter (terminal digit preference). This study aimed to assess the precision (number of digits) of breast cancer tumor diameters and whether they are affected by terminal digit preference. Furthermore, we aimed to assess the agreement between mammographic and histopathologic tumor diameter measurements. Material and Methods: This national registry study included reported mammographic and registered histopathologic tumor diameter information from the Cancer Registry of Norway for invasive breast cancers diagnosed during 2012-2016. Terminal digit preference was assessed using histograms. Agreement between mammographic and histopathologic measurements was assessed using the intraclass correlation coefficient (ICC) and Bland-Altman plots. Results: Mammographic, histopathologic, or both tumor measurements were available for 7792, 13,541 and 6865 cases, respectively. All mammographic and 97.2% of histopathologic tumor diameters were recorded using whole mm. Terminal digits of zero or five were observed among 38.7% and 34.8% of mammographic and histopathologic measurements, respectively. There was moderate agreement between the two measurement methods (ICC ¼ 0.52, 95% CI: 0.50-0.53). On average, mammographic measurements were 1.26 mm larger (95% limits of agreement: À22.29-24.73) than histopathologic measurements. This difference increased with increasing tumor size. Conclusion: Terminal digit preference was evident among breast cancer tumor diameters in this nationwide study. Further studies are needed to investigate the potential extent of under-staging and under-treatment resulting from this measurement error.

show abstract

“…A series of studies have documented that provision of care according to national guidelines positively influence clinical outcomes. Effects from refined diagnostics, e.g., increasing use of preoperative MRI and improved quality of pathology reports have been demonstrated to influence resection rates, local recurrence rates and survival in e.g., breast cancer, colorectal cancer, gastroesophageal cancer and melanoma [30][31][32][33][34][35][36][37][38][39]. In e.g., colorectal cancer, lung cancer and urinary bladder cancer, registry data have been used to demonstrate increasing survival rates in large cohorts [30,34,[39][40][41][42].…”

Section: Monitoring Changing Principles Of Carementioning

confidence: 99%

The power of empirical data; lessons from the clinical registry initiatives in Scandinavian cancer care

Nilbert

Thomsen

Jensen³

et al. 2020

Acta Oncologica

View full text Add to dashboard Cite

Background: In Scandinavia, there is a strong tradition for research and quality monitoring based on registry data. In Denmark, Norway and Sweden, 63 clinical registries collect data on disease characteristics, treatment and outcome of various cancer diagnoses and groups based on process-related and outcome-related variables. Aim: We describe the cancer-related clinical registries, compare organizational structures and quality indicators and provide examples of how these registries have been used to monitor clinical performance, develop prediction models, assess outcome and provide quality benchmarks. Further, we define unmet needs such as inclusion of patient-reported outcome variables, harmonization of variables and barriers for data sharing. Results and conclusions: The clinical registry framework provides an empirical basis for evidencebased development of high-quality and equitable cancer care. The registries can be used to follow implementation of new treatment principles and monitor patterns of care across geographical areas and patient groups. At the same time, the lessons learnt suggest that further developments and coordination are needed to utilize the full potential of the registry initiative in cancer care.

show abstract

Melanoma staging: Varying precision and terminal digit clustering in Breslow thickness data is evident in a population-based study

Cited by 10 publications

References 25 publications

<p>Brodalumab for the treatment of moderate-to-severe psoriasis: case series and literature review</p>

<p>Brodalumab for the treatment of moderate-to-severe psoriasis: case series and literature review</p>

Terminal digit preference: a source of measurement error in breast cancer diameter reporting

The power of empirical data; lessons from the clinical registry initiatives in Scandinavian cancer care

Contact Info

Product

Resources

About